In recent years, there has been increasing interest in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as innovative drugs for the treatment of type 2 diabetes mellitus (T2DM) and obesity. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.